查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1908133

人工智慧藥物重定位（DR）市場規模、佔有率和趨勢分析報告：按組件、技術、適應症、最終用途、地區和細分市場預測，2026-2033年

Artificial Intelligence In Drug Repurposing Market Size, Share & Trends Analysis Report By Component, By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

人工智慧在藥物重定位（DR）市場概述

2025 年全球藥物重定位人工智慧 (AI DR) 市場規模估計為 12.3 億美元，預計到 2033 年將達到 57.1 億美元。

預計從 2026 年到 2033 年，該市場將以 21.18% 的複合年成長率成長。對經濟高效的藥物開發的需求不斷成長、藥物重定位 (DR) 臨床試驗數量的增加以及罕見疾病和複雜疾病盛行率的上升是推動市場成長的關鍵因素。

此外，對精準醫療和標靶藥物研發的日益重視，以及運算能力和雲端運算基礎設施的改進，也是推動市場成長的因素。

對具成本效益藥物研發策略日益成長的需求是推動人工智慧藥物重定位（DR）市場成長的主要動力。傳統的藥物研發過程通常耗時十年以上，每種藥物的研發成本往往超過20億美元。藥物重定位（DR）提供了一種策略，透過將已通過核准或在臨床實驗藥物用於新的適應症，從而繞過早期安全性測試。人工智慧透過快速分析海量的生物學、化學和臨床數據，識別新的藥物-疾病關聯，從而加速這一過程。這縮短了研發時間和成本，使其成為製藥公司和醫療機構在經濟上可行的全新藥物研發替代方案。將人工智慧融入藥物重定位（DR）能夠有效解決產業面臨的關鍵挑戰，在提高效率的同時降低相關風險和投資。

人工智慧系統整合了包括基因組學、蛋白質組學和代謝體學在內的多體學數據，並結合生物醫學文獻和真實世界患者記錄，以識別先前未被發現的、細微的藥物-標靶相互作用。這些方法克服了傳統假設驅動發現的局限性，能夠識別多藥理學候選藥物和協同藥物組合。例如，2025年4月，Plex Research與Ginkgo Bioworks合作，對GDPx2資料集（一項大規模化合物誘導基因表現轉錄組調查）進行人工智慧輔助分析。此次合作旨在闡明新的疾病機制，發現新的治療應用，並加速藥物重定位（DR），且已通過實驗數據進行了嚴格檢驗。

此外，罕見病患疾病率的不斷上升進一步推動了市場成長。例如，根據《採血針》 2024年3月發布的數據，約有3億人將患有罕見疾病，影響全球約3.5%至5.9%的人口。此外，約80%的罕見疾病源於遺傳因素，其中約70%在兒童發病。人工智慧可以幫助分析來自罕見疾病隊列的有限資料集，並從現有藥物中識別出候選治療藥物，從而加快患者獲得治療的速度。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 人工智慧在藥物重定位（DR）的市場變數、趨勢與範圍

  • 市場譜系展望
    • 母市場展望
    • 相關及配套市場展望
  • 市場動態
  • 案例研究結果
  • 用於藥物重定位（DR）的人工智慧市場分析工具
    • 產業分析：波特五力模型
    • PESTEL 分析

第4章：藥物重定位（DR）人工智慧市場：按組件分類的估算與趨勢分析

  • 全球藥物重定位人工智慧市場：按組件分類的差異分析
  • 全球藥物重定位人工智慧市場規模及趨勢分析（按組件分類，2021-2033年）
  • 軟體平台
  • 服務

第5章：藥物重定位（DR）人工智慧市場：按技術分類的估算與趨勢分析

  • 全球人工智慧藥物重定位（DR）市場技術變革分析
  • 全球藥物重定位人工智慧市場規模及技術趨勢分析（2021-2033年）
  • 機器學習/深度學習
  • 自然語言處理（NLP）
  • 知識圖譜/基於網路的人工智慧
  • 生成式人工智慧/大規模語言模型（LLM）
  • 電腦視覺

第6章：藥物重定位（DR）人工智慧市場：按適應症分類的估算與趨勢分析

  • 全球人工智慧藥物重定位（DR）市場：按適應症分類的差異分析
  • 全球藥物重定位人工智慧市場規模及趨勢分析（依適應症分類，2021-2033年）
  • 腫瘤學
  • 神經病學
  • 心臟病學
  • 感染疾病
  • 罕見疾病和孤兒疾病
  • 其他

第7章 人工智慧在藥物重定位（DR）市場的應用：按最終用途分類的估算和趨勢分析

  • 全球人工智慧藥物重定位（DR）市場：按最終用途分類的差異分析
  • 全球人工智慧藥物重定位（DR）市場規模及趨勢分析（依最終用途分類，2021-2033年）
  • 製藥和生物技術公司
  • 受託研究機構（CRO）
  • 學術和研究機構
  • 其他

第8章：人工智慧在藥物重定位（DR）領域的市場：按地區分類的估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模及預測趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 公司/競爭對手分類
  • 策略規劃
  • 2025年商業市場分析
  • 公司簡介/列表
    • BostonGene Corporation
    • BenevolentAI
    • Innophore
    • Delta4.ai
    • BioXcel Therapeutics Inc.
    • BullFrog AI Holdings, Inc.
    • Graphwise
    • Owkin, Inc
    • Insilico Medicine
    • Healx
Product Code: GVR-4-68040-755-3

Artificial Intelligence In Drug Repurposing Market Summary

The global artificial intelligence in drug repurposing market size was estimated at USD 1.23 billion in 2025 and is projected to reach USD 5.71 billion by 2033, growing at a CAGR of 21.18% from 2026 to 2033. Rising demand for cost-effective drug development, increasing clinical trials in drug repurposing, and growing prevalence of rare and complex diseases are significant factors contributing to market growth.

In addition, growing focus on precision medicine and targeted drug development and improvements in computing power and cloud infrastructure are some other factors fueling market growth.

The rising demand for cost-effective drug development strategies substantially drives the AI in drug repurposing market. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments.

AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.

Furthermore, the rising prevalence of rare diseases propels market growth further. For instance, according to the data published by The Lancet Journal in March 2024, around 300 million people live with rare diseases, affecting around 3.5% - 5.9% of the global population. Moreover, around 80% of rare diseases are genetically caused, almost 70% of which are present in childhood. AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs, thus expediting treatment access.

Global Artificial Intelligence In Drug Repurposing Market Report Segmentation

This report forecasts, revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented global artificial intelligence in drug repurposing market report based on component, technology, application, end use, and region.

  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Software & Platforms
  • Services
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Machine Learning/Deep Learning
  • Natural Language Processing (NLP)
  • Knowledge Graphs & Network-Based AI
  • Generative AI & Large Language Models (LLMs)
  • Computer Vision
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Rare & Orphan Diseases
  • Other Therapeutic Areas
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Component Segment
    • 1.2.2. Technology Segment
    • 1.2.3. Application Segment
    • 1.2.4. End Use
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Artificial Intelligence in Drug Repurposing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for cost-effective drug development,
      • 3.2.1.2. Increasing clinical trials in drug repurposing
      • 3.2.1.3. Growing focus on precision medicine and targeted drug development
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Highly regulated industry
      • 3.2.2.2. High computational costs and infrastructure requirements
    • 3.2.3. Market opportunity analysis
    • 3.2.4. Market challenges analysis
  • 3.3. Case Study Insights
  • 3.4. Artificial Intelligence in Drug Repurposing Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape
      • 3.4.2.6. Social Landscape

Chapter 4. Artificial Intelligence in Drug Repurposing Market: Component Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Artificial Intelligence in Drug Repurposing Market Component Movement Analysis
  • 4.3. Global Artificial Intelligence in Drug Repurposing Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
  • 4.4. Software & Platforms
    • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5. Services
    • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Artificial Intelligence in Drug Repurposing Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Artificial Intelligence in Drug Repurposing Market Technology Movement Analysis
  • 5.3. Global Artificial Intelligence in Drug Repurposing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 5.4. Machine Learning/Deep Learning
    • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.5. Natural Language Processing (NLP)
    • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Knowledge Graphs & Network-Based AI
    • 5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Generative AI & Large Language Models (LLMs)
    • 5.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.8. Computer Vision
    • 5.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Artificial Intelligence in Drug Repurposing Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Artificial Intelligence in Drug Repurposing Market Application Movement Analysis
  • 6.3. Global Artificial Intelligence in Drug Repurposing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5. Neurology
    • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Cardiology
    • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Infectious Diseases
    • 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.8. Rare & Orphan Diseases
    • 6.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.9. Other Therapeutic Areas
    • 6.9.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Artificial Intelligence in Drug Repurposing Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Artificial Intelligence in Drug Repurposing Market End Use Movement Analysis
  • 7.3. Global Artificial Intelligence in Drug Repurposing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5. Contract Research Organizations (CROs)
    • 7.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6. Academic & Research Institutes
    • 7.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Artificial Intelligence in Drug Repurposing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. U.S.
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.4.2. Canada
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.4.3. Mexico
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.2. Germany
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.3. France
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.4. Italy
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.5. Spain
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.6. Norway
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.7. Sweden
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Regulatory framework
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Regulatory framework
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.3. India
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.4. Australia
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.6. Thailand
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.2. Argentina
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.3. UAE
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.4. Kuwait
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Regulatory framework
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2025
  • 9.4. Company Profiles/Listing
    • 9.4.1. BostonGene Corporation
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. BenevolentAI
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Innophore
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Delta4.ai
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. BioXcel Therapeutics Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. BullFrog AI Holdings, Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Graphwise
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Owkin, Inc
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Insilico Medicine
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Healx
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global AI in drug repurposing market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 4 Global AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 5 Global AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 6 Global AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 7 North America AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 9 North America AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 10 North America AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 11 North America AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 12 U.S. AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 13 U.S. AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 14 U.S. AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 15 U.S. AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Canada AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 17 Canada AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 18 Canada AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 19 Canada AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Mexico AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 21 Mexico AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 22 Mexico AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 23 Mexico AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Europe AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 25 Europe AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 26 Europe AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 27 Europe AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 28 Europe AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 29 UK AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 30 UK AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 31 UK AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 32 UK AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 33 Germany AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 34 Germany AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 35 Germany AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 36 Germany AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 37 France AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 38 France AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 39 France AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 40 France AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Italy AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 42 Italy AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 43 Italy AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 44 Italy AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Spain AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 46 Spain AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 47 Spain AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Spain AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 49 Denmark AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 50 Denmark AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 51 Denmark AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Denmark AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 53 Sweden AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 54 Sweden AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 55 Sweden AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 56 Sweden AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Norway AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 58 Norway AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 59 Norway AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 60 Norway AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 66 China AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 67 China AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 68 China AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 69 China AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 70 Japan AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 71 Japan AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 72 Japan AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 73 Japan AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 74 India AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 75 India AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 76 India AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 77 India AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 78 South Korea AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 79 South Korea AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 80 South Korea AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 81 South Korea AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Australia AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 83 Australia AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 84 Australia AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 85 Australia AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 86 Thailand AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 87 Thailand AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 88 Thailand AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 89 Thailand AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Latin America AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 91 Latin America AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 92 Latin America AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 93 Latin America AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 94 Latin America AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 95 Brazil AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 96 Brazil AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 97 Brazil AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 98 Brazil AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 99 Argentina AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 100 Argentina AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 101 Argentina AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 102 Argentina AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 103 MEA AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 104 MEA AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 105 MEA AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 106 MEA AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 107 MEA AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 108 South Africa AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 109 South Africa AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 110 South Africa AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 111 South Africa AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 116 UAE AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 117 UAE AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 118 UAE AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 119 UAE AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 120 Kuwait AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 121 Kuwait AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 122 Kuwait AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 123 Kuwait AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Market formulation & validation
  • Fig. 5 AI in drug repurposing market: Market outlook
  • Fig. 6 AI in drug repurposing market: Segment outlook
  • Fig. 7 AI in drug repurposing market: Competitive landscape outlook
  • Fig. 8 Parent market outlook
  • Fig. 9 AI in drug repurposing market driver impact
  • Fig. 10 AI in drug repurposing market restraint impact
  • Fig. 11 AI in drug repurposing market: Component outlook and key takeaways
  • Fig. 12 AI in drug repurposing market: Component movement analysis
  • Fig. 13 Software & platform market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 14 Services market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 15 AI in drug repurposing market: Technology outlook and key takeaways
  • Fig. 16 AI in drug repurposing market: Technology movement analysis
  • Fig. 17 Machine learning/deep learning market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Natural language processing (NLP) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Knowledge graphs & network-based AI market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Generative AI & large language models (LLMs) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Computer vision market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 AI in drug repurposing market: Application outlook and key takeaways
  • Fig. 23 AI in drug repurposing market: Application movement analysis
  • Fig. 24 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Neurology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Cardiology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Rare & orphan diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Other therapeutic areas market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 AI in drug repurposing market: End use outlook and key takeaways
  • Fig. 31 AI in drug repurposing market: End use movement analysis
  • Fig. 32 Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Contract research organizations (CROs) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Global AI in drug repurposing market: Regional outlook and key takeaways
  • Fig. 37 Global AI in drug repurposing market: Regional movement analysis
  • Fig. 38 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. key country dynamics
  • Fig. 40 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Canada key country dynamics
  • Fig. 42 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Mexico key country dynamics
  • Fig. 44 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 UK key country dynamics
  • Fig. 47 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Germany key country dynamics
  • Fig. 49 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 France key country dynamics
  • Fig. 51 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Italy key country dynamics
  • Fig. 53 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Spain key country dynamics
  • Fig. 55 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Denmark key country dynamics
  • Fig. 57 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Sweden key country dynamics
  • Fig. 59 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Norway key country dynamics
  • Fig. 61 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Japan key country dynamics
  • Fig. 64 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 China key country dynamics
  • Fig. 66 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Thailand key country dynamics
  • Fig. 70 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 South Korea key country dynamics
  • Fig. 72 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Australia key country dynamics
  • Fig. 74 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Brazil key country dynamics
  • Fig. 77 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Argentina key country dynamics
  • Fig. 79 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 South Africa key country dynamics
  • Fig. 82 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Saudi Arabia key country dynamics
  • Fig. 84 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 UAE key country dynamics
  • Fig. 86 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Kuwait key country dynamics
  • Fig. 88 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)